Journal of AdvancedMedical and Dental Sciences Research

Aim: To examine the adjuvant impact of Metformin with ATT and ATT alone. Methods: A comparative observational study was conducted in the Department of Respiratory Medicine. 120 patients were included in this study. Patients with new smear positive pulmonary tuberculosis, Aged above 13 years, patients who never received treatment with multidrug anti Tb therapy for more than a week and Is willing to attend a treatment centre for supervised treatment and remain within in the study. Results: The average time taken for sputum smear conversion was significantly lower in the Metformin group in comparison with the control group (p = 0.015, unpaired t-test). It was about 3.5 (±1.82) weeks in Metformin group while it was 4.6 (±2.42) weeks in the control group. All the subjects enrolled in the study were non-diabetics. At the time of enrollment, their fasting and post prandial blood sugar and HbA1c values were measured and only those who were having normal values were selected for the study. The mean fasting blood sugar was 97.7±8.5mg/dl and 93.4±11.2mg/dl and the mean sugar values at post prandial state was 128.31±24.21mg/dl and 126.87±30.41 mg/dl in control and Metformin groups respectively at the time of enrollment. In control group, the baseline HbA1c was 4.67±0.63 % and it was 4.83±0.81% in Metformin group. Conclusion: We concluded that the supports Metformin added to standard ATT potentially benefiting TB patients as evidenced by significant reduction in the time needed for sputum smear conversion and reduction in the occurrence of drug resistance.